Han Xu, M.d., Ph.d., Fapcr, Sponsor-investigator, Irb Chair

This early-phase study tests a new biologic treatment in 20 people with HIV who have no AIDS symptoms. The goal is to see if the therapy can lower the amount of virus in the blood and help the immune system fight HIV better. The treatment is given through the skin, and researcher…

This study looks at how small differences in genes (called SNPs) might influence how well the drug topotecan works and what side effects it causes in people with small cell lung cancer. Researchers will test 600 patients who are already taking topotecan, using precise DNA sequenc…

This study looks at how genetic differences in 600 people with a high-risk breast condition called LCIS affect their response and side effects from the drug raloxifene. Participants take raloxifene for at least 90 days, and researchers analyze their DNA to find gene variations li…

This study looks at how tiny genetic differences (called SNPs) in ALK and CYP3A4 genes influence how well the drug alectinib works and what side effects it causes in people with ALK-positive non-small cell lung cancer. Researchers will collect blood samples from 600 patients and …